Seventy-six million people will suffer from blindness by 2020. Age-related retinal disorders – macular degeneration (AMD) and diabetic macular edema (DME) are two of the leading causes of blindness in the world. About 200,000 new cases of advanced, age-related AMD identified each year in the United States and between 14.9 and 21.5 million cases of early AMD, and between 3.9 and 4.8 million cases of late AMD is expected in Europe by 2040. The complexity of eye anatomy presents challenges for treatment. Current treatment, intravitreal injections (IVI) are the highest growth medical procedure in the globe, with an estimated 20 million intravitreal injections globally in 2016. Ranibizumab, treatment blocking vascular endothelial growth factor (VEGF), which promotes blood vessel growth, costs approximately $2,000 in USA and €1000 per injection. Patients may need up to 12 injection per year. Additionally, this treatment significantly affects patient comfort.
MicroSert has developed BlueDot – a novel, long-acting release (LAR) ocular implant for the sustained delivery of biologics and small molecules for the treatment of retinal diseases. BlueDot is implantable to the tear duct and releases therapeutic inside the eye. Implantation requires one-step office-based procedure using proprietary implantation device with safety monitoring system and with no incision needed. BlueDot is refillable and lasts up to two years.